In today’s biotech financing climate, early-stage founders are facing a paradox: breakthrough science has never been more sophisticated, yet the capital required to advance it has become harder to secure. Seed and pre-Series A companies are increasingly expected to generate meaningful proof-of-concept data before attracting institutional investment — often without the infrastructure to do so.
A new Maryland-based contract development and manufacturing organization (CDMO) is stepping into that gap.
Launched last year, Xcellon Biologics has introduced the Xcellerate Program, an initiative designed to lower the upfront cost and technical barriers for startups developing complex biologics and antibody-drug conjugates (ADCs). The program aims to make high-end development capabilities accessible at a stage when many young companies need them most — but can least afford them.
According to program materials , Xcellerate provides early-stage companies with structured support across preclinical development, feasibility strategy, proof-of-concept studies, and early CMC planning — all intended to help teams reach IND-enabling milestones more efficiently.
At a time when Maryland’s innovation community is navigating slower venture deployment and tighter grant cycles, the initiative reflects a broader question: how can ecosystem players work together to help startups survive long enough to reach their next inflection point?
Learn more: https://xcellon.bio/our-company/
Building Infrastructure for the “In-Between” Stage
Xcellon Biologics positions itself as a specialized CDMO advancing ADCs and complex biologics through innovative conjugation platforms. The Xcellerate Program builds on that technical focus by offering value-driven services — including antibody generation, conjugation chemistry, analytical support, and in vitro testing — at reduced or at-cost structures for qualifying startups.
The goal is not simply outsourced experimentation. It is structured early decision-making.
The program emphasizes candidate selection strategy, linker-payload evaluation, developability assessments, and early CMC roadmap development — the types of foundational work that can dramatically influence whether a company advances efficiently or stalls under technical debt.
For startups building in the ADC space, these decisions are particularly consequential. Antibody-drug conjugates combine biologics and cytotoxic payloads, requiring specialized expertise in protein engineering, conjugation chemistry, stability analysis, and manufacturability. Missteps in early design can compound later in development, adding cost and time at precisely the wrong moment.
By integrating proof-of-concept data generation — including in vitro cytotoxicity, stability testing, and early toxicology support — with CMC strategy, Xcellon is attempting to compress the path between discovery and IND readiness.
In an environment where investors increasingly scrutinize translational clarity, that compression matters.
A Maryland Company Betting on Maryland
Xcellon’s commitment to the region extends beyond its service model.
The company recently secured a TEDCO Equitech Growth Grant to support its infrastructure buildout — a signal of both state-level backing and long-term commitment to operating within Maryland’s life sciences ecosystem.
In recent years, Maryland has doubled down on biomanufacturing expansion, workforce initiatives, and innovation funding. At the same time, the region has experienced the same macroeconomic headwinds impacting biotech nationally: venture slowdowns, capital efficiency pressures, and greater expectations on early technical validation.
In that context, a local CDMO offering structured, lower-cost early development support represents more than a business strategy. It is ecosystem infrastructure.
Rather than exporting early development work to distant hubs, programs like Xcellerate keep scientific execution — and associated talent growth — anchored locally.
Experienced Leadership, Targeted Focus
Xcellon Biologics was co-founded by Yuk Chun Chiu, who serves as Chief Operating Officer, alongside Abhishake Chhibber and Thomas Haag as board members. Chiu brings more than 20 years of GMP manufacturing and biopharmaceutical leadership experience, including prior roles at AstraZeneca, Cytovance Biologics, and Bayer, according to the company.
That operational background is notable in the ADC space, where manufacturing complexity can quickly become a bottleneck. Experience scaling GMP systems and engineering processes can influence how early programs are architected — not just how they are produced later.
For startups without in-house manufacturing veterans, that perspective can be the difference between a clean IND path and repeated course corrections.
Why This Matters Now
Across the BioHealth Capital Region, founders are recalibrating expectations. Investors are asking for more data before writing checks. Grant agencies are more competitive. And many early-stage teams are being forced to choose between capital conservation and technical acceleration.
Programs like Xcellerate represent a hybrid solution: lowering the financial barrier to generate the very data that unlocks future capital.
If successful, the model could help early biologics and ADC startups reach critical value-creation milestones without over-diluting or overextending during fragile growth phases.
For Maryland specifically, it signals a maturation of the ecosystem. When local infrastructure players proactively support startups — particularly in specialized, high-complexity domains like ADCs — it strengthens the region’s ability to compete nationally.
The biotech financing cycle will eventually rebound. But the companies that survive this period will likely be those that found ways to build smarter, earlier.
With Xcellerate, Xcellon Biologics is positioning itself as a partner in that bridge — helping Maryland’s next generation of therapeutic innovators move from promising science to actionable proof.
And in a moment when doing more with less has become the norm, that kind of ecosystem-aligned infrastructure may prove just as important as capital itself.
